APA (7th ed.) Citation

N, A., J, T., Y, K., F, I., A, I., K, T., . . . H, K. (2018). Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection. Journal of gastroenterology, 53(9), 1089. https://doi.org/10.1007/s00535-018-1445-3

Chicago Style (17th ed.) Citation

N, Akuta, et al. "Potent Viral Suppression and Improvements in Alpha-fetoprotein and Measures of Fibrosis in Japanese Patients Receiving a Daclatasvir/asunaprevir/beclabuvir Fixed-dose Combination for the Treatment of HCV Genotype-1 Infection." Journal of Gastroenterology 53, no. 9 (2018): 1089. https://doi.org/10.1007/s00535-018-1445-3.

MLA (9th ed.) Citation

N, Akuta, et al. "Potent Viral Suppression and Improvements in Alpha-fetoprotein and Measures of Fibrosis in Japanese Patients Receiving a Daclatasvir/asunaprevir/beclabuvir Fixed-dose Combination for the Treatment of HCV Genotype-1 Infection." Journal of Gastroenterology, vol. 53, no. 9, 2018, p. 1089, https://doi.org/10.1007/s00535-018-1445-3.